The adjunct role of pharmacotherapy in multimodal treatment of paediatric functional neurological disorder
Frontiers in Psychiatry · 17.07.2025 · 16
DOI: 10.3389/fpsyt.2025.1560873 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Psychiatry, online erschienen am 17.07.2025. Verfasst von Rynagh Cummins und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychological Medicine, The Children's Hospital at Westmead, Sydney, NSW, Australia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Rehabilitation for children with functional neurological disorder (FND) requires a biopsychosocial intervention: physiotherapy, psychotherapy, pharmacotherapy, school attendance, and family work. This study documents the pharmacotherapeutic element and its rationale.
Methods
Medication use was documented in 158 children with FND (41 boys, 117 girls, aged 8.50–17.58; mean 13.78) admitted into the Mind-Body Program.
Results
On presentation, children with FND had high levels of functional impairment, school loss, and comorbid psychiatric, functional, and medical disorders. On admission, 63% (n=95) were on medications. During admission, 130 (82.3%) children had pharmacotherapy interventions: dose adjustment, initiation, or discontinuation. 88.6% (n=140) were discharged on medications. Pharmacotherapy targets included: antidepressants for anxiety/depression (n=111; 70.3%); antipsychotics for extreme anxiety/arousal (n=73; 46.2%); melatonin for sleep (n=64; 40.5%); α agonists and β blockers, for arousal, sleep initiation, and trauma-related nightmares (n=58; 36.7%); iron/vitamin supplementation (n=30; 19.0%); and medications for functional gut symptoms (n=28; 17.7%) and comorbid pain (n=20; 12.7%).
Conclusions
Pharmacotherapy is used as an adjunct in paediatric FND to down-regulate the stress system, reset the circadian clock, manage pain, and treat comorbid disorders. Pharmacotherapy and its concomitant placebo effects scaffold the child to enable engagement in all components of the therapeutic process and return to healthy function.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychological Medicine, The Children's Hospital at Westmead, Sydney, NSW, Australia.
- Center School of Psychological Sciences, University of Tasmania, Launceston, TAS, Australia.
- Child Youth Mental Health Service North (CYMHSN), Launceston, TAS, Australia.
- Department of Psychiatry, Harvard Medical School, and McLean Hospital, Belmont, MA, United States.
- University of Sydney Medical School, Sydney, NSW, Australia.
- The Children's Hospital at Westmead, and Disciplines of Psychiatry and Child and Adolescent Health, University of Sydney Medical School, Sydney, NSW, Australia.
Zitieren
APA
Cummins, R., Hawkes, C., Longworth, J., Scher, S., & Kozlowska, K. (2025). The adjunct role of pharmacotherapy in multimodal treatment of paediatric functional neurological disorder. Frontiers in Psychiatry, 16. https://doi.org/10.3389/fpsyt.2025.1560873
Vancouver
Cummins R, Hawkes C, Longworth J, Scher S, Kozlowska K. The adjunct role of pharmacotherapy in multimodal treatment of paediatric functional neurological disorder. Frontiers in Psychiatry. 2025;16. doi:10.3389/fpsyt.2025.1560873
BibTeX
@article{Cummins2025,
author = {Cummins, Rynagh and Hawkes, Clare and Longworth, Judy and Scher, Stephen and Kozlowska, Kasia},
title = {The adjunct role of pharmacotherapy in multimodal treatment of paediatric functional neurological disorder},
journal = {Frontiers in Psychiatry},
year = {2025},
volume = {16},
doi = {10.3389/fpsyt.2025.1560873}
}
EUVIMED